{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:41:19Z","timestamp":1781656879536,"version":"3.54.5"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019320","name":"ONL Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xops.2025.100954","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:58:19Z","timestamp":1759553899000},"page":"100954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ONL1204 for the Treatment of Geographic Atrophy: Phase Ib Study Evaluating Safety, Tolerability, and Efficacy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-5216","authenticated-orcid":false,"given":"David M.","family":"Kleinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga S.","family":"Borkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn H.","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-2166","authenticated-orcid":false,"given":"Andrew J.","family":"Kocab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Puscas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Wietholter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7188-1579","authenticated-orcid":false,"given":"Lori L.","family":"Kesteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Zacks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100954_bib1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100954_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review","volume":"36","author":"Desai","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100954_bib3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/OPX.0b013e31821988c1","article-title":"Update on geographic atrophy in age-related macular degeneration","volume":"88","author":"Biarn\u00e9s","year":"2011","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.xops.2025.100954_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Beckman initiative for macular research classification committee. Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100954_bib5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ophtha.2019.07.022","article-title":"Prevalence, risk, and genetic association of reticular pseudodrusen in age-related macular degeneration: age-related eye disease study 2 report 21","volume":"126","author":"Domalpally","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100954_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2025.100954_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","article-title":"Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy","volume":"128","author":"Wykoff","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100954_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100954_bib9","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-Month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100954_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archopht.120.11.1435","article-title":"The role of apoptosis in age-related macular degeneration","volume":"120","author":"Dunaief","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.100954_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.xops.2025.100954_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/jcm11030592","article-title":"Cell death in AMD: the rationale for targeting fas","volume":"11","author":"Zacks","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2025.100954_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/tvst.7.6.40","article-title":"The rate of progression of geographic atrophy decreases with increasing baseline lesion size Even after the square root transformation","volume":"7","author":"Mon\u00e9s","year":"2018","journal-title":"Transl Vis Sci Technol"},{"issue":"5-a Suppl","key":"10.1016\/j.xops.2025.100954_bib14","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:01:47Z","timestamp":1770818507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666914525002520"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100954","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ONL1204 for the Treatment of Geographic Atrophy: Phase Ib Study Evaluating Safety, Tolerability, and Efficacy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100954"}}